Hysterectomy: The most cost-effective solution for heavy menses

Article

Using available evidence on effectiveness, cost and utility values, hysterectomy is a more cost-effective solution for heavy menstrual bleeding than first- or second-generation endometrial ablation techniques or the levonorgestrel-releasing intrauterine system, according to a new UK analysis.

Using available evidence on effectiveness, cost, and utility values, hysterectomy is a more cost-effective solution for heavy menstrual bleeding than first- or second-generation endometrial ablation techniques or the levonorgestrel-releasing intrauterine system (Mirena; Bayer Healthcare, Morristown, New Jersey), according to the results of a recent analysis from the United Kingdom.

The researchers found that although hysterectomy is more expensive than the other 3 options tested, it produces more quality adjusted life years (QALYs) than the other strategies and is, therefore, more likely to be considered cost-effective. They calculated the incremental cost-effectiveness ratio for hysterectomy compared with Mirena to be $2,350 per additional QALY and the incremental cost-effectiveness ratio for hysterectomy compared with second-generation ablation to be $1,603. Second-generation ablation techniques and Mirena are less expensive, less invasive, and produce more QALYs than first-generation ablation techniques.

Although the results are consistent with those of other studies, the authors caution that they are highly sensitive to the utility values used. They also report that their results somewhat conflict with what is actually going on in clinical practice, which is that a reduction in the use of hysterectomy for heavy menstrual bleeding has occurred over the past decade, with women and their physicians favoring second-generation ablation techniques and Mirena.

Roberts TE, Tsourapas A, Middleton LJ, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ. 2011;342:d2202.

Recent Videos
Supreme Court upholds mifepristone access: Implications for women's health | Image Credit: linkedin.com
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
© 2024 MJH Life Sciences

All rights reserved.